Autopsy report · NCT01522443

Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer

Cause of deathOther Automatic label, confidence 0.3, unverified. How labels are made.

“Stopped after the outcome of cabozantinib Phase 3 CRPC study XL184-307.”

The sponsor’s own words in the registry.

Life of this trial

Registered 2 months before it started.
Ran for about 2 years 10 months before it stopped.
119 participants enrolled.
Results were posted on the registry 3 years 4 months after it ended.

Vital statistics

Status: Terminated
Phase: Phase 3
Sponsor: Exelixis
Sponsor type: Industry
Conditions: Prostate Cancer; Castration Resistant Prostate Cancer; Pain; Prostatic Neoplasms
Interventions: cabozantinib; mitoxantrone; prednisone
Participants: 119
Sites: 82
Countries: Australia, Canada, Ireland, United Kingdom, United States

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.